Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00777036 · OUTCOME

Major Cytogenetic Response (MCyR) Rate in Cohort 2

A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib · Source last updated 2025-08-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of participants
Interval / dispersion
95% Confidence Interval
Time frame
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)

What was measured

Major Cytogenetic Response (MCyR) rate was defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response. The percentage of treated participants in each arm with MCyR is reported.

Analysis population: Secondary efficacy endpoint pre-specified only for participants treated in Cohort 2

Groups in this outcome

Cohort 2

Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Cohort 217

Reported measurements

Source class 1
Values in percentage of participants · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Cohort 252.9Not reported27.877.0Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        27.8
        upper Limit
        77.0
        value
        52.9
denoms
  1. counts
    1. group Id
      OG000
      value
      17
    units
    Participants
description
Major Cytogenetic Response (MCyR) rate was defined as the proportion of all treated participants who achieved a complete (0%) or partial (1%-35% Ph+ metaphases in at least 20 metaphases in bone marrow) cytogenetic response. The percentage of treated participants in each arm with MCyR is reported.
dispersion Type
95% Confidence Interval
groups
  1. description
    Children and adolescents with Ph+ ALL, AP-CML or BP-CML who were resistant or intolerant to, or relapsed after imatinib therapy received dasatinib tablets at a dose schedule of 80 mg/m2 QD on a continuous oral regimen.
    id
    OG000
    title
    Cohort 2
param Type
NUMBER
population Description
Secondary efficacy endpoint pre-specified only for participants treated in Cohort 2
reporting Status
POSTED
time Frame
From first dose of study therapy until 30 days after last dose (Assessed up to September 2016, approximately 90 months)
title
Major Cytogenetic Response (MCyR) Rate in Cohort 2
type
SECONDARY
unit Of Measure
percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice